Nuvalent Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $46.67
- Today's High:
- $48.555
- Open Price:
- $47.91
- 52W Low:
- $15.565
- 52W High:
- $50.585
- Prev. Close:
- $48.1
- Volume:
- 148553
Company Statistics
- Market Cap.:
- $2.74 billion
- Book Value:
- 7.394
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -20.21%
- Return on Equity TTM:
- -29.7%
Company Profile
Nuvalent Inc had its IPO on 2021-07-29 under the ticker symbol NUVL.
The company operates in the Healthcare sector and Biotechnology industry. Nuvalent Inc has a staff strength of 78 employees.
Stock update
Shares of Nuvalent Inc opened at $47.91 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $46.67 - $48.56, and closed at $46.98.
This is a -2.33% slip from the previous day's closing price.
A total volume of 148,553 shares were traded at the close of the day’s session.
In the last one week, shares of Nuvalent Inc have increased by +1.12%.
Nuvalent Inc's Key Ratios
Nuvalent Inc has a market cap of $2.74 billion, indicating a price to book ratio of 7.398 and a price to sales ratio of 0.
In the last 12-months Nuvalent Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Nuvalent Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nuvalent Inc’s operating margin was 0% while its return on assets stood at -20.21% with a return of equity of -29.7%.
In Q2, Nuvalent Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Nuvalent Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.86 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nuvalent Inc’s profitability.
Nuvalent Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -23.4833. Its price to sales ratio in the trailing 12-months stood at 0.
Nuvalent Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $441.95 million
- Total Liabilities
- $20.80 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Nuvalent Inc ended 2024 with $441.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $441.95 million while shareholder equity stood at $421.15 million.
Nuvalent Inc ended 2024 with $0 in deferred long-term liabilities, $20.80 million in other current liabilities, 6000.00 in common stock, $-214359000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $70.87 million and cash and short-term investments were $431.24 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Nuvalent Inc’s total current assets stands at $436.99 million while long-term investments were $0 and short-term investments were $360.37 million. Its net receivables were $0 compared to accounts payable of $8.12 million and inventory worth $0.
In 2024, Nuvalent Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Nuvalent Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $46.98
- 52-Week High
- $50.585
- 52-Week Low
- $15.565
- Analyst Target Price
- $50
Nuvalent Inc stock is currently trading at $46.98 per share. It touched a 52-week high of $50.585 and a 52-week low of $50.585. Analysts tracking the stock have a 12-month average target price of $50.
Its 50-day moving average was $44.26 and 200-day moving average was $35.97 The short ratio stood at 13.55 indicating a short percent outstanding of 0%.
Around 445.2% of the company’s stock are held by insiders while 10676.4% are held by institutions.
Frequently Asked Questions About Nuvalent Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.